Second interims analysis of the ARA Plus study – Breast Cancer (BC) adjuvant chemotherapy (CT) with and without darbepoetin alfa (Aranesp®) – Analysis serious adverse events

Adjuvant chemotherapy improves survival in node positive breast cancer. TAC is one of the most effective regimens, but it is associated with higher frequency of anemia and chemotherapy-induced neutropenia (CIN). The erythropoiesis stimulating factor (ESF) support of chemotherapy, its complications and survival effect remain unclear. Erythropoetins do prevent chemotherapy-associated anemia (CAA) and subsequent fatigue syndrome but their potential influence on survival is still unclear. Two aims of this analysis are to investigate the amount of hemoglobin (Hb) response and the correlation between CT, growth factor…